Evotec and Lygature announced their cooperation in a new initiative for the development of novel antibacterial agents today: Gram-Negative Antibacterials NOW (\u201cGNA NOW\u201d). The new GNA NOW project, led by Evotec, managed by Lygature and funded by the Innovative Medicines Initiative (IMI), will work on the development of novel antibacterial agents to battle antimicrobial resistance in gram-negative bacteria. The multi-stakeholder consortium includes nine other partners from academia, industry and SMEs: Nosopharm, BIOASTER, Helmholtz Centre for Infection Research, North Bristol National Health Service Trust, University of Liverpool, Inserm, Erasmus Medical Center, Medical University of Vienna, and Fraunhofer IME.<\/p>\n\n\n\n
Collectively, the GNA NOW members will progress three programmes in parallel with the goal of bringing one through completion of Phase I studies and one reaching Investigational New Drug (IND) stage and\/or up to two programmes reaching clinical development candidate stage, by 2024.<\/p>\n\n\n\n
GNA NOW is supported by the IMI, a joint initiative between the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA), of which Evotec is a member. The IMI, the world’s largest public-private partnership (PPP) in life sciences, will match Evotec\u2019s in-kind contribution with a \u20ac 12 m grant over the next six years, to fund the activities of the consortium. This award will allow the eleven partners of this consortium to build European platforms of excellence around each step of the critical path for drug discovery and development. European experts will join forces to contribute to \u201cmechanism of action elucidation\u201d, \u201cmedicinal chemistry and design\u201d, \u201cin vitro profiling\u201d, \u201cpre-candidate efficacy studies\u201d, \u201ccandidate PK\/PD studies\u201d, \u201csafety and ADME\u201d, \u201cCMC\u201d, as well as \u201cclinical studies and modelling\u201d. <\/p>\n\n\n\n
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: \u201cWe are extremely glad to initiate GNA NOW with the backing of the European Commission and the EFPIA. Bacterial infections are a growing threat around the globe and are driving the need for innovative therapeutics with new mechanisms of action. GNA NOW gives us the opportunity to join forces with leading institutions of both the public and the private sector across Europe to develop new gram-negative antibacterial agents as quickly and as efficiently as possible.\u201d<\/p>\n\n\n\n
Dr Kristina Orrling, program manager at Lygature and GNA NOW project coordinator, commented: \u201cBy joining forces we can fend off a grim future where a simple urinary infection can be fatal. Together, we\u2019ll strengthen the antibacterial arsenal.\u201d<\/p>\n\n\n\n
About antibiotic-resistant bacteria and GNA NOW Antibiotic-resistant bacteria were estimated to be responsible for 670,000 infections and 33,110 attributable deaths in the EU and the European Economic Area (EEA) in 2015. From a global perspective, antimicrobial resistance could kill up to ten million people every year by 2050, which could cost up to \u20ac 94 trillion ($ 100 tn). In February 2017, the WHO published a list of priority pathogens for the development of new antibiotics. Carbapenem-resistant gram-negative bacteria (Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumannii) were at the top of that list, with critical priority.<\/p>\n\n\n\n
GNA NOW is an Evotec-led joint initiative of eleven partners, project managed by Lygature, with the goal of developing novel antibacterial agents and bringing one of the three simultaneously developed compounds through completion of Phase I studies plus one compound reaching Investigational New Drug (IND) stage and\/or up to two compounds reaching clinical development candidate stage, by 2024.<\/p>\n\n\n\n
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853979. The JU receives support from the European Union\u2019s Horizon 2020 research and innovation programme and EFPIA. <\/p>\n\n\n\n